MonumenTAL-1 Results a Pivotal Phase 2 Trial of Talquetamab in RRMM Multiple Myeloma 2 Mins Read7 “Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the…
